Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355406 | 0.90 | KMT2A (0.37) | KMT2AL3MBTL1KDM4ETDP1 | |
| SCHEMBL13098219 | 0.76 | HTR2A (0.54) | KMT2AFFAR1HTR2A | |
| SCHEMBL6898751 | 0.72 | HSD17B10 (0.50) | L3MBTL1TSHRHSD17B10KDM4EHTR2A | |
| SCHEMBL8099830 | 0.72 | MAOA (0.45) | L3MBTL1KDM4EHTR2A | |
| SCHEMBL9193592 | 0.72 | KMT2A (0.36) | KMT2AL3MBTL1TSHRHSD17B10KDM4E | |
| SCHEMBL2154504 | 0.72 | KMT2A (0.47) | KMT2AL3MBTL1KDM4ETDP1 | |
| SCHEMBL13015764 | 0.72 | ENPP2 (0.49) | KMT2AKDM4ETDP1FFAR1 | |
| SCHEMBL9197674 | 0.71 | KMT2A (0.38) | KMT2AL3MBTL1TSHRKDM4ETDP1 | |
| SCHEMBL9552411 | 0.71 | KMT2A (0.35) | KMT2AL3MBTL1TSHRHSD17B10KDM4E | |
| SCHEMBL846409 | 0.71 | HSD17B10 (0.58) | TSHRHSD17B10KDM4EHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703825-B2 | Compounds, use thereof as medicaments, and method of preparation thereof | UNIVERSITE DE LORRAINE (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | CYP11B2, NPM1, B2M | KMT2A 2941/4885L3MBTL1 4103/4885TSHR 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.